The effects of mipomersen, a secondgeneration antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia

References

• Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two firstin-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129(9), 1022–1032 (2014). •• Systematic Review Of Lomitapide And Mipomersen.
   Google Scholar
• Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein (a) in homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20, 522–528 (2000).
   Google Scholar
• Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60(8), 716–721 (2012).
   Google Scholar
• Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Basis of Inherited Disease (8th Edition). Scriver CR, Beaud AL, Sly WS, Valle D (Eds.), McGraw-Hill, NY, USA, 2863–2913 (2001).
   Google Scholar
• Sjouke B, Kusters DM, Kindt I et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. (2014) (Epub ahead of print).
   Google Scholar
• Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. National Lipid Association Expert Panel on Familial Hypercholesterolemia: familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S9–S17 (2011). • Review Of Familial Hypercholesterolemia With An Emphasis On The Genetic Basis Of This Disease. Important Recommendations On Screening And Diagnosis Are Included.
   Google Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478–3490 (2013).
   Google Scholar
• Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid- lowering therapy. Circulation 124, 2202–2207 (2011). •• An Important Evaluation Of The Impact Of Statins On Mortality In Homozygous Familial Hypercholesterolemia (Hofh). This Review Looks At The Age Of Death In Hofh Patients Prior To Statins (Generally By 18 Years) And Age Of Death Following The Introduction Of Statins (Age 33 Years).
   Google Scholar
• Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon. Outcomes Res. 5, 189–192 (2013).
   Google Scholar
• Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J. Clin. Lipidol. 8(1), 18–28. (2014).
   Google Scholar
• Khachadurian AK, Uthman SM. Experiences with homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr. Metab. 15, 132 (1973).
   Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/ AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Col. Cardiol. doi: 10.1016/j.jacc.2013.11.002. (2013) (Epub ahead of print).
   Google Scholar
• American Academy of Pediatrics. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Natl Heart Lung Blood Inst. NIH Publication No 12, 7486A (2012). www.nhlbi.nih.gov/files/docs/peds_guidelines_sum.pdf
   Google Scholar
• Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemia: recommendations for the National Lipid Association Expert Panel of Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S30–S37 (2011).
   Google Scholar
• Thompson GR. Heart-UK LDL Apheresis Working Group: recommendations for the use of LDL apheresis. Atherosclerosis 198, 247–255 (2008).
   Google Scholar
• Moghadasian MH, Frolich JJ, Saleem M et al. Surgical management of dyslipidemia: clinical and experimental evidence. J. Invest. Surg. 14, 71–78 (2001).
   Google Scholar
• Lopez-Santamaria M, Migliazza L, Gamez M et al. Liver transplantation in patients with homozygous familial hypercholesterolemia previously treated by end-to-side portacaval shunt and ileal bypass. J. Pediatr. Surg. 35, 630–633 (2000).
   Google Scholar
• Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am. J. Cardiovasc. Drugs 13(4), 285–296 (2013).
   Google Scholar
• Cuchel M, Meagher EA, duToit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, Phase 3 study. Lancet 381, 40–46 (2013).
   Google Scholar
• Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148–156 (2007).
   Google Scholar
• Lomitapide, Sponsor Background Package. US FDA. New Drug Application #203858 Aegerion (2012). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM323843.pdf
   Google Scholar
• Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113–2120 (2013).
   Google Scholar
• Zamecnik PC. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75(1), 280–284 (1978).
   Google Scholar
• Ricotta DN, Frishman W. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol. Rev. 20, 90–95 (2012).
   Google Scholar
• Aboul-Fadl T. Antisense oligonucleotides: the state of the art. Curr. Med. Chem. 12(19), 2193–214 (2005).
   Google Scholar
• Crooke RM, Graham MJ. Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. Clin. Lipidol. 6(6), 675–692 (2011).
   Google Scholar
• Agrawal S, Jiang Z, Zhao Q et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl Acad. Sci. USA, 94(6) 2620–2625 (1997).
   Google Scholar
• Crooke ST & Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br. J. Clin. Pharmacol. 76(2), 269–276 (2013). • Review Of Antisense Technology In General, As Well As A Detailed Look At The Pharmacological Properties Of Mipomersen.
   Google Scholar
• Yu RZ, Lemonidis KM, Graham MJ et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein b-100. Biochem. Pharmcol. 77, 910–919 (2009).
   Google Scholar
• Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid. Res. 46(5), 872–884 (2005).
   Google Scholar
• Mullick AE, Fu W, Graham MJ et al. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. J. Lipid. Res. 52(5), 885–896 (2011).
   Google Scholar
• Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35(3), 460–468 (2007).
   Google Scholar
• Yu RZ, Geary RS, Flaim JD et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2’-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet. 48(1), 39–50 (2009).
   Google Scholar
• Li Z, Hard ML, Grundy JS, Singh T, von Moltke LL, Boltje I. Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. J. Cardiovasc. Pharmacol.64(2), 164–171 (2014).
   Google Scholar
• Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729–1735 (2006).
   Google Scholar
• Akdim F, Tribble DL, Flaim JD et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur. Heart. J. 32(21), 2650–2659 (2011).
   Google Scholar
• Akdim F, Visser ME, Tribble DL et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol. 105, 1413–1419 (2010a).
   Google Scholar
• Akdim F, Stroes ES, Sijbrands EJ et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55, 1611–1618 (2010b).
   Google Scholar
• Visser ME, Akdim F, Tribble DL et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid. Res. 51(5), 1057–1062 (2010).
   Google Scholar
• Visser ME, Wagener G, Baker BF et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. 33(9), 1142–1149 (2012).
   Google Scholar
• Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet 375, 998–1006 (2010). •• Largest Double-Blind, Placebo-Controlled Trial Of Mipomersen-Treated Hofh Patients Who Experienced A Mean Ldl Reduction Of 25% (Absolute Reduction Of 113 Mg/Dl).
   Google Scholar
• Stein EA, Dufour R, Gagne C et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126(19), 2283–2292 (2012).
   Google Scholar
• McGowan MP, Tardif JC, Ceska R et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLOS ONE 7(11), e49006 (2012).
   Google Scholar
• Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson, M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62(23), 24–30 (2013).
   Google Scholar
• Santos RD, Duell PB, East C et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. (2013) (Epub ahead of print).
   Google Scholar
• Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23(2), 133–140 (2012).
   Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K et al. For the European Atherosclerosis Society Consensus Panel: lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844–2853 (2010).
   Google Scholar
• Davidson MH, Ballantyne CM, Jacobson TA et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol. 5(5), 338–367 (2011).
   Google Scholar
• Reiner Z, Catapano AL, De Backer G et al. ESC/EAS guidelines for the management of dyslipidemias: the Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart. J. 32(14), 1769–1818 (2011).
   Google Scholar
• US Department of Health and Human Services, US FDA. Guidance for Industry. Drug-induced Liver Injury: premarketing clinical evaluation. (2009). www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf.
   Google Scholar
• Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J. Inherit. Metab. Dis. 37, 333–339 (2014).
   Google Scholar
• Visser ME, Lammers NM, Nederveen AJ et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia 54, 2113–2121 (2011).
   Google Scholar
• KYNAMRO (mipomersen sodium). Injection solution for subcutaneous injection. Full prescribing information. January 2013. Genzyme Corporation, a Sanofi Company (MA, USA). www.kynamro.com/~/media/Kynamro/Files/KYNAMRO-PI.pdf.">www.kynamro.com/~/media/Kynamro/Files/KYNAMRO-PI.pdf.
   Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341–1350 (2010).
   Google Scholar
• Lazo M, Hernaez R, Bonekamp S et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343, d6891 (2011).
   Google Scholar